Selin Kolsuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Selin Kolsuz has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Abdur Rehman
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publications - Cao Cuong Le
The University of Texas MD Anderson Cancer Center
2 shared publications Chun-Yen Lin
The University of Texas MD Anderson Cancer Center
2 shared publications- Faezeh Darbaniyan
The University of Texas MD Anderson Cancer Center
2 shared publications - Federico Mario Aletti
The University of Texas MD Anderson Cancer Center
2 shared publications - Fuliang Chu
The University of Texas MD Anderson Cancer Center
2 shared publications
Latest Publications
- Open Access
Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies
Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.
Open AccessChimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies
Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.
- Open Access
A novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies and multiple myeloma, but its extension to T-cell lymphomas (TCLs) has been constrained by the paucity of antigens that can be safely targeted. While targeting pan-T antigens broadens the therapeutic reach across various TCLs, it carries a substantial risk of immunosuppression and infection. Here, we report killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 2 (KIR3DL2/CD158k) as a viable target for CAR T-cell therapy against a wide range of TCLs. Using single-cell RNA-seq data analysis and flow cytometric phenotyping, we observed that KIR3DL2 expression is restricted to a subset of mature NK cells and a minor fraction of CD8⁺ T cells, with negligible expression in other healthy adult tissues. Among TCLs, KIR3DL2 expression was noted in various subtypes of cutaneous and systemic TCLs. Anti-KIR3DL2 CAR constructs (3DL2CARs) efficiently and selectively redirected T cells against antigen-positive cell lines but not isogenic KIR3DL2-negative counterparts, with antigen-specific signaling, cytotoxicity, proliferation, and cytokine production. Importantly, 3DL2CART cells produced sustained tumor regression and prolonged survival in two distinct cell line-derived xenograft models of cutaneous TCL and in one patient-derived xenograft model of hepatosplenic TCL. 3DL2CART cells exhibited minimal off-target activity against bystander immune cells and showed no appreciable fratricide. To mitigate the risk of tumor cell contamination in autologous CAR T-cell products, we established a two-tiered strategy that integrates immunomagnetic depletion of KIR3DL2-positive tumor cells with in vivo activation of a safety switch if inadvertently transduced malignant cells contribute to immune escape. Together, our results establish the preclinical efficacy and safety of 3DL2CART-cell therapy and support its clinical translation. This approach may offer a targeted alternative to pan-T-cell-directed CAR T-cell strategies for patients with relapsed/refractory cutaneous and systemic TCLs, addressing a critical unmet clinical need.
Open AccessA novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies and multiple myeloma, but its extension to T-cell lymphomas (TCLs) has been constrained by the paucity of antigens that can be safely targeted. While targeting pan-T antigens broadens the therapeutic reach across various TCLs, it carries a substantial risk of immunosuppression and infection. Here, we report killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 2 (KIR3DL2/CD158k) as a viable target for CAR T-cell therapy against a wide range of TCLs. Using single-cell RNA-seq data analysis and flow cytometric phenotyping, we observed that KIR3DL2 expression is restricted to a subset of mature NK cells and a minor fraction of CD8⁺ T cells, with negligible expression in other healthy adult tissues. Among TCLs, KIR3DL2 expression was noted in various subtypes of cutaneous and systemic TCLs. Anti-KIR3DL2 CAR constructs (3DL2CARs) efficiently and selectively redirected T cells against antigen-positive cell lines but not isogenic KIR3DL2-negative counterparts, with antigen-specific signaling, cytotoxicity, proliferation, and cytokine production. Importantly, 3DL2CART cells produced sustained tumor regression and prolonged survival in two distinct cell line-derived xenograft models of cutaneous TCL and in one patient-derived xenograft model of hepatosplenic TCL. 3DL2CART cells exhibited minimal off-target activity against bystander immune cells and showed no appreciable fratricide. To mitigate the risk of tumor cell contamination in autologous CAR T-cell products, we established a two-tiered strategy that integrates immunomagnetic depletion of KIR3DL2-positive tumor cells with in vivo activation of a safety switch if inadvertently transduced malignant cells contribute to immune escape. Together, our results establish the preclinical efficacy and safety of 3DL2CART-cell therapy and support its clinical translation. This approach may offer a targeted alternative to pan-T-cell-directed CAR T-cell strategies for patients with relapsed/refractory cutaneous and systemic TCLs, addressing a critical unmet clinical need.
- Open Access
- 13 August 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1)
Evolutionary adaptations in iron capture via type II pyoverdine in XDR Pseudomonas aeruginosa ST235
Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen responsible for a wide range of human infections. The ST235 high-risk clone, which emerged in Europe and spread globally, is particular...
- 13 August 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1)
Open AccessEvolutionary adaptations in iron capture via type II pyoverdine in XDR Pseudomonas aeruginosa ST235
Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen responsible for a wide range of human infections. The ST235 high-risk clone, which emerged in Europe and spread globally, is particular...
- Open Access
- 14 January 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 153, 107781
Risk factors and preventive role of vaccination in adult tetanus fatality: a systematic review of reported cases (1990-2024) and meta-analysis
- 14 January 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 153, 107781
Open AccessRisk factors and preventive role of vaccination in adult tetanus fatality: a systematic review of reported cases (1990-2024) and meta-analysis
- Open Access
- 5 January 2024
- Published by AVES YAYINCILIK A.Ş. in Acta Orthopaedica et Traumatologica Turcica
- Vol. 58 (5) , 290-295
Comparison of the effects of ultrasound-guided steroid injection and anatomic landmark-guided injection on pain and disability in greater trochanteric pain syndrome
Objective: Greater trochanteric pain syndrome (GTPS) is a prevalent condition that can significantly affect patient comfort and function. This study aims to compare the effectiveness of ultrasound (USG)-guided and anatomic landmark-guided corticosteroid injections in managing GTPS. Methods: Patients diagnosed with GTPS received either USG or anatomic landmark-guided corticosteroid injections. Pain scores (Visual Analog Scale, VAS) and functional outcomes (modified Harris Hip Score, HHS) were assessed at baseline, 1 month, and 1 year postinjection. Cost-effectiveness was calculated using public and private payor pricing from June 2024. Results: Both treatment groups exhibited significant improvements in pain and function. The USG group demonstrated greater initial improvements at the 1-month mark, particularly in VAS activity and HHS. However, these differences between the groups converged over time, with similar long-term outcomes observed in these parameters. The USG-guided injections showed more pronounced initial benefits, especially for patients with higher initial pain levels and lower functional scores. USG was found to be more cost-effective in terms of HHS, but not VAS measures. Conclusion: While both USG and anatomic landmark-guided injections are effective for managing GTPS, USG-guided injections may provide greater initial relief in pain and function, particularly for patients with higher initial pain levels. USG does not demonstrate longterm superiority over anatomic injections. The study underscores the importance of evaluating long-term outcomes to comprehensively assess the sustained effectiveness of different treatment strategies for GTPS. Level of Evidence: Level III, Therapeutic study. Cite this article as: Topaloglu M, Cihad Gedik C, Sarikaya D, et al. Comparison of the effects of ultrasound-guided steroid injection and anatomic landmark-guided injection on pain and disability in greater trochanteric pain syndrome. Acta Orthop Traumatol Turc., 2024;58(5):290-295.
- 5 January 2024
- Published by AVES YAYINCILIK A.Ş. in Acta Orthopaedica et Traumatologica Turcica
- Vol. 58 (5) , 290-295
Open AccessComparison of the effects of ultrasound-guided steroid injection and anatomic landmark-guided injection on pain and disability in greater trochanteric pain syndrome
Objective: Greater trochanteric pain syndrome (GTPS) is a prevalent condition that can significantly affect patient comfort and function. This study aims to compare the effectiveness of ultrasound (USG)-guided and anatomic landmark-guided corticosteroid injections in managing GTPS. Methods: Patients diagnosed with GTPS received either USG or anatomic landmark-guided corticosteroid injections. Pain scores (Visual Analog Scale, VAS) and functional outcomes (modified Harris Hip Score, HHS) were assessed at baseline, 1 month, and 1 year postinjection. Cost-effectiveness was calculated using public and private payor pricing from June 2024. Results: Both treatment groups exhibited significant improvements in pain and function. The USG group demonstrated greater initial improvements at the 1-month mark, particularly in VAS activity and HHS. However, these differences between the groups converged over time, with similar long-term outcomes observed in these parameters. The USG-guided injections showed more pronounced initial benefits, especially for patients with higher initial pain levels and lower functional scores. USG was found to be more cost-effective in terms of HHS, but not VAS measures. Conclusion: While both USG and anatomic landmark-guided injections are effective for managing GTPS, USG-guided injections may provide greater initial relief in pain and function, particularly for patients with higher initial pain levels. USG does not demonstrate longterm superiority over anatomic injections. The study underscores the importance of evaluating long-term outcomes to comprehensively assess the sustained effectiveness of different treatment strategies for GTPS. Level of Evidence: Level III, Therapeutic study. Cite this article as: Topaloglu M, Cihad Gedik C, Sarikaya D, et al. Comparison of the effects of ultrasound-guided steroid injection and anatomic landmark-guided injection on pain and disability in greater trochanteric pain syndrome. Acta Orthop Traumatol Turc., 2024;58(5):290-295.